RecruitingObesityOverweightChronic Weight Management

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Eligible age

18–79 yrs

Accepts

All genders

Locations

32 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

You may qualify if…

✓ Signed informed consent
✓ BMI ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) and presence of ≥1 of the obesity related comorbidities.

You may not qualify if…

✕ Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.
✕ Self-reported change in body weight \>5 kg within 3 months before Screening.
✕ Have prior or planned surgical or non-surgical treatment for obesity.
✕ Have or plan to have endoscopic and/or device-based therapy for obesity.
✕ Have obesity induced by other endocrine disorders.
✕ Impaired renal function at Screening
✕ Chronic malabsorption